

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

IOBR

RRID:SCR_025619

Type: Tool

Proper Citation

IOBR (RRID:SCR_025619)

Resource Information

URL: <https://github.com/IOBR/IOBR>

Proper Citation: IOBR (RRID:SCR_025619)

Description: Software R package to perform comprehensive analysis of tumor microenvironment and signatures for immuno-oncology. Used for comprehensively interpreting multi-omics data.

Synonyms: Immuno-Oncology Biological Research

Resource Type: software resource, data processing software, software application, data analysis software

Defining Citation: [PMID:34276676](#)

Keywords: interpreting multi-omics data, perform comprehensive analysis,

Funding: National Natural Science Foundation of China ;
Guangzhou Planned Project of Science and Technology

Availability: Free, Available for download, Freely available,

Resource Name: IOBR

Resource ID: SCR_025619

License: GNU GPL v3

Record Creation Time: 20240815T053252+0000

Record Last Update: 20260804T043834+0000

Ratings and Alerts

No rating or validation information has been found for IOBR.

No alerts have been found for IOBR.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Fang C, et al. (2025) Transcriptomic and morphologic vascular aberrations underlying FCDIIb etiology. *Nature communications*, 16(1), 3320.

Yang T, et al. (2025) ZNF143 as a diagnostic biomarker: Insights from gene expression and immune cell infiltration in COPD and asthma. *Medicine*, 104(43), e45317.

Li X, et al. (2025) Mapping glioma progression: single-cell RNA sequencing illuminates cell-cell interactions and immune response variability. *Discover oncology*, 16(1), 302.

Zhong Y, et al. (2025) Identification of SETD4 as an Onco-Immunological Biomarker Encompassing the Tumor Microenvironment, Prognoses, and Therapeutic Responses in Various Human Cancers. *Immunity, inflammation and disease*, 13(1), e70126.

Huang W, et al. (2025) Identification of molecular subtypes and a prognostic signature based on machine learning and purine metabolism-related genes in breast cancer. *Medicine*, 104(21), e42288.

Qiao S, et al. (2025) Targeting SQLE-mediated cholesterol metabolism to enhance CD8+ T cell activation and immunotherapy efficacy in hepatocellular carcinoma. *Journal for immunotherapy of cancer*, 13(9).

Huang R, et al. (2025) Integrated mendelian randomization and bioinformatics approach unveiling the immunological and prognostic significance of FBXO2 in breast cancer. *Discover oncology*, 16(1), 2187.

Yu Q, et al. (2025) Knockdown TNF family prognosis index crucial gene PDE4B promoted PANoptosis of ovarian carcinoma cell:Based in vitro and in vivo experiments. *Translational oncology*, 56, 102333.

Hua M, et al. (2025) Multiomic machine learning on lactylation for molecular typing and prognosis of lung adenocarcinoma. *Scientific reports*, 15(1), 3075.

Liu L, et al. (2025) Revealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer. *iScience*, 28(1), 111612.

Ke J, et al. (2025) Single-cell and bulk transcriptome analyses revealed the role of macrophage cholesterol metabolism in atherosclerosis. *Lipids in health and disease*, 25(1), 3.

Wang B, et al. (2025) SMR-guided molecular subtyping and machine learning model reveals novel prognostic biomarkers and therapeutic targets in non-small cell lung adenocarcinoma. *Scientific reports*, 15(1), 1640.

Zhang H, et al. (2025) UBC9: a novel therapeutic target in papillary thyroid carcinoma. *Journal of endocrinological investigation*, 48(5), 1101.

Yu Y, et al. (2025) Multi-omics identification of a polyamine metabolism related signature for hepatocellular carcinoma and revealing tumor microenvironment characteristics. *Frontiers in immunology*, 16, 1570378.

Ou F, et al. (2025) Integrating machine learning and multi-omics analysis to unveil key programmed cell death patterns and immunotherapy targets in kidney renal clear cell carcinoma. *Scientific reports*, 15(1), 18403.

Cao J, et al. (2025) Cellular heterogeneity and cytokine signatures in acute myeloid leukemia: A novel prognostic model. *Translational oncology*, 52, 102194.

Lei Y, et al. (2025) Disulfidptosis in pediatric AML: a multi-omics approach to risk stratification and potential therapeutic strategy. *Cancer cell international*, 25(1), 199.

Zhao J, et al. (2025) Cancer-associated fibroblasts and metabolic reprogramming predict pathologic response to neoadjuvant PD-1 blockade in resected non-small cell lung cancer. *Cellular oncology (Dordrecht, Netherlands)*, 48(4), 1105.

Li XX, et al. (2025) Identification of novel cholesterol metabolism-related biomarkers for thyroid cancer to predict the prognosis, immune infiltration, and drug sensitivity. *Discover oncology*, 16(1), 1608.

Van Laethem JL, et al. (2025) CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. *Cell reports. Medicine*, 6(10), 102407.